Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer

Authors:
  • VLVito Lorusso
    Vito Lorusso
  • NPNicola Panza
    Nicola Panza
  • PCPasquale Comella
    Pasquale Comella
  • GNGianpaolo Nicolella
    Gianpaolo Nicolella
  • ABAndrea Bianco
    Andrea Bianco
  • GCGiuseppe De Cataldis
    Giuseppe De Cataldis
  • AIAnnunziato Iannelli
    Annunziato Iannelli
  • DBDomenico Bilancia
    Domenico Bilancia
  • MBMario Belli
    Mario Belli
  • BMBruno Massidda
    Bruno Massidda
  • FPFrancovito Piantedosi
    Francovito Piantedosi

Abstract
PURPOSE: To evaluate whether the addition of gemcitabine (G) to vinorelbine (V) improves survival and quality of life (QoL) among elderly patients with advanced non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients with NSCLC aged ≥ 70 years with advanced disease were randomly allocated to receive V 30 mg/m2 on days 1 and 8 every 3 weeks or G 1,200 mg/m2 + V 30 mg/m2 on days 1 and 8 every 3 weeks. The estimated sample size was 120 patients per arm, but an interim analysis of survival was planned based on the first 60 patients per arm. RESULTS: In May 1999, the survival data were analyzed of 120 eligible patients (V group = 60; G + V group = 60) who had been randomized from June 1997 to February 1999. Forty-nine patients had stage IIIB disease, and 71 had stage IV. At a median potential follow-up of 14 months (range, 3 to 22 months), 93 patients had died (G + V group = 41; V group = 52). In the G + V group, median survival time was 29 weeks and projected 1-year survival was 30%; these values were 18 weeks and 13% in the V group. According to multivariate Cox analysis, the risk of death in the G + V arm compared with the V arm was 0.48 (95% confidence interval, 0.29 to 0.79; P < .01). Combination therapy was also associated with a clear delay in symptom and QoL deterioration. The overall response rates were 22% and 15% in the G + V and V groups, respectively. CONCLUSION: In elderly patients with NSCLC, G + V treatment is associated with significantly better survival than is V alone.

This publication has 23 references indexed in Scilit: